GB1327740A - Vaccine preparations containing adjuvants - Google Patents

Vaccine preparations containing adjuvants

Info

Publication number
GB1327740A
GB1327740A GB1344472A GB1344472A GB1327740A GB 1327740 A GB1327740 A GB 1327740A GB 1344472 A GB1344472 A GB 1344472A GB 1344472 A GB1344472 A GB 1344472A GB 1327740 A GB1327740 A GB 1327740A
Authority
GB
United Kingdom
Prior art keywords
vaccine
march
specified
oxidized
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1344472A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recherche et Industrie Therapeutiques
Original Assignee
Recherche et Industrie Therapeutiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recherche et Industrie Therapeutiques filed Critical Recherche et Industrie Therapeutiques
Publication of GB1327740A publication Critical patent/GB1327740A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
GB1344472A 1971-03-26 1972-03-22 Vaccine preparations containing adjuvants Expired GB1327740A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00128530A US3839555A (en) 1971-03-26 1971-03-26 Vaccine adjuvant and method

Publications (1)

Publication Number Publication Date
GB1327740A true GB1327740A (en) 1973-08-22

Family

ID=22435777

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1344472A Expired GB1327740A (en) 1971-03-26 1972-03-22 Vaccine preparations containing adjuvants

Country Status (9)

Country Link
US (1) US3839555A (enExample)
BE (1) BE781028R (enExample)
CA (1) CA980251A (enExample)
CY (1) CY840A (enExample)
DE (1) DE2214229A1 (enExample)
FR (1) FR2130132B2 (enExample)
GB (1) GB1327740A (enExample)
IN (1) IN139166B (enExample)
NL (1) NL7202698A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039597A3 (en) * 2003-10-24 2005-07-14 Nutricia Nv Immunemodulating oligosaccharides

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4243663A (en) * 1976-06-25 1981-01-06 Ichiro Azuma Glycolipid compositions for transplanted tumor immunotherapy
FR2590674B1 (fr) * 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
US4761281A (en) * 1986-04-22 1988-08-02 Immunomed Corporation Vaccine from Dirofilaria extracts
DD298884A5 (de) * 1990-07-10 1992-03-19 Charite Der Humboldt-Universitaet,De Impfstoffe gegen virale antigene und verfahren zu ihrer herstellung
DE4141970C2 (de) * 1991-12-16 1998-02-19 Charite Med Fakultaet Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1137540A (en) * 1966-12-20 1968-12-27 Nat Res Dev Improvements relating to the treatment of hypocalcaemia
CA928218A (en) * 1969-06-17 1973-06-12 Recherche Et Industrie Therapeutiques R.I.T. Antiinfectious compositions and process for their preparation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039597A3 (en) * 2003-10-24 2005-07-14 Nutricia Nv Immunemodulating oligosaccharides
US8557794B2 (en) 2003-10-24 2013-10-15 N.V. Nutricia Immunemodulating oligosaccharides

Also Published As

Publication number Publication date
CA980251A (en) 1975-12-23
NL7202698A (enExample) 1972-09-28
US3839555A (en) 1974-10-01
CY840A (en) 1976-09-10
DE2214229A1 (de) 1972-09-28
IN139166B (enExample) 1976-05-15
FR2130132A2 (enExample) 1972-11-03
BE781028R (fr) 1972-09-22
FR2130132B2 (enExample) 1975-12-26

Similar Documents

Publication Publication Date Title
GB1327740A (en) Vaccine preparations containing adjuvants
DE69231673D1 (de) Escherichia coli impfstoffe auf der basis von o-polysaccharid-protein konjugaten
GB1252371A (enExample)
YU153291A (sh) Poboljšani vakcinski preparati
GB1481048A (en) 7-hydroxy-delta8-tetrahydrocannabinols
NZ510419A (en) A vaccine adjuvant that is an oil-in-water immunoslimulant emulsion
GB1422973A (en) Process for preparing adsorbed vaccines
NZ235316A (en) Vaccine containing capsular polysaccharide conjugated to recombinant c protein of a group b streptococcus, production and use against b streptococcus infection
GB1477797A (en) Hydroxypropyl starch acetate having elastic properties
ES475509A1 (es) Un metodo de preparacion de una vacuna polivalente eficaz contra el streptococcus pneumoniae que comprende polisacari-dos capsulares altamente purificados de estreptococcus pneu-moniae.
ES339689A1 (es) Procedimiento para la preparacion de 11 ibeta, 17 alfa-di- hidroxiesteroides.
GB1401588A (en) Vaccine and method for its production
HU171383B (hu) Sposob izoljacii immunogennykh vehhestv iz shtammov pas
GB1290141A (enExample)
ES380650A1 (es) Un procedimiento para preparar una composicion antiinfec- ciosa contra agentes que dependen de la repeticion intrace- lular.
GB1409149A (en) Quecetin derivatives and pharmaceutical uses thereof
GB1295666A (enExample)
CA962593A (en) Highly attenuated newcastle disease virus vaccine and production thereof
CA946566A (en) Recovery of a water-soluble polymer powder from an aqueous gel of solid polymer
GB1339057A (en) Process for the preparation of acetyl derivatives of glycosides
GB1258095A (enExample)
Geddes et al. Chloramphenicol resistance in the typhoid bacillus
CA1007567A (en) Vaccine adjuvants
GB1212966A (en) 9beta,10alpha-STEROIDS AND A PROCESS FOR THE PREPARATION THEREOF
GB1406289A (en) Consolidation of soil

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee